00:00
Elapsed
Q 1 / 20
00:00
Question 1
1. In October 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology of Medicine for their groundbreaking efforts in inhibiting the impact of cancer in patients through immunotherapy. James P. Allison, 70-year-old immunologist and native Texan, works at the prestigious Anderson Cancer Center in Houston. Tasuku Honjo is a 76-year-old immunologist and native of Kyoto, Japan who currently leads a variety of important medical research efforts at Kyoto University. Their research efforts span several decades, in two extremely different national contexts, but their recent international collaborations have reignited the profession over the last ten years.
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
Allison and Honjo began their most recent collaborative research in the
Your Answer: Option(s)
Correct Answer: Option(s) C
Rationale
Allison and Honjo began their most recent collaborative research in the 2000s.
The extract clearly mentions that their recent international collaborations, which can be inferred as their most recent collaborative research, have reignited the profession over the last ten years. Given that the text was written in 2018, the last ten years would refer to the period starting in the 2000s.
A) 1970s
The 1970s is incorrect as the extract does not mention any collaboration between the two scientists during this period. Their research efforts span several decades, but the specific start of their most recent collaborative research is stated to be within the last ten years from 2018, placing it in the 2000s.
B) 1980s
The 1980s is also incorrect. Although the extract acknowledges that their individual research efforts have spanned several decades, it does not suggest that their most recent collaborative research began in the 1980s. It states that their recent international collaborations began within the last ten years, which would place the start of this phase of their work in the 2000s.
D) 1990s
The 1990s is not correct as well. While the scientists have been conducting research for decades, the extract specifies that their most recent collaborative research began within the last ten years from 2018, which again points to the 2000s.
Conclusion
The correct answer is the 2000s, as the extract clearly states that Allison and Honjo's most recent collaborative research, which reignited the profession, began within the last ten years from 2018. The other options—1970s, 1980s, and 1990s—are incorrect as they do not align with the timeline provided in the extract. This highlights the importance of their work in recent years, which has led to significant advancements in the field of cancer immunology.
Select an answer to continue →
Question 2
1. In October 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology of Medicine for their groundbreaking efforts in inhibiting the impact of cancer in patients through immunotherapy. James P. Allison, 70-year-old immunologist and native Texan, works at the prestigious Anderson Cancer Center in Houston. Tasuku Honjo is a 76-year-old immunologist and native of Kyoto, Japan who currently leads a variety of important medical research efforts at Kyoto University. Their research efforts span several decades, in two extremely different national contexts, but their recent international collaborations have reignited the profession over the last ten years.
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
According to the article, which statement is true?
Your Answer: Option(s)
Correct Answer: Option(s) B
Rationale
James P. Allison and Tasuku Honjo have discovered new relationships between certain proteins and cancer.
James P. Allison and Tasuku Honjo, both renowned immunologists, have been awarded the Nobel Prize for their groundbreaking efforts in cancer immunotherapy. Their research has focused on finding new strategies for "inhibiting the brakes of our immune systems" through T-cell immunotherapy, which implies the discovery of new relationships between certain proteins and cancer.
A) CTLA-4 and PD-1 are two types of cancer that have been cured by CTLA-4 and PD-1.
This statement is incorrect. The extract does not mention CTLA-4 and PD-1 as types of cancer. Moreover, these are known as immune checkpoint proteins, not cancer types. They are involved in the regulation of immune responses, part of the focus of Allison and Honjo's work.
B) James P. Allison and Tasuku Honjo have discovered new relationships between certain proteins and cancer.
This is the correct answer. Their work in inhibiting immune system regulation, specifically through T-cell immunotherapy, suggests the discovery of new relationships between certain proteins, such as immune checkpoint proteins, and cancer.
C) James P. Allison and Tasuku Honjo just recently started studying cancer.
This statement is false. The extract clearly states that their research efforts span several decades, indicating a long-term commitment to cancer research.
D) All cancers have been cured by James P. Allison and Tasuku Honjo's therapeutic practices.
This is incorrect. While their research has significantly contributed to the field of cancer immunotherapy and led to the development of new therapeutic practices, the extract does not claim that all cancers have been cured by their work. It mentions that cancer remains the second leading cause of global mortality rates.
Conclusion
Based on the extract, the only true statement among the choices is that James P. Allison and Tasuku Honjo have been uncovering new relationships between certain proteins and cancer, specifically in the context of T-cell immunotherapy. The other statements either provide misinformation or make exaggerated claims that are not supported by the text. The work of Allison and Honjo represents significant progress in the field of cancer immunotherapy, but it does not claim to have cured all cancers or to be a recent endeavor. Their work is ongoing and continues to ignite interest and investment in immunotherapy research.
Select an answer to continue →
Question 3
1. In October 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology of Medicine for their groundbreaking efforts in inhibiting the impact of cancer in patients through immunotherapy. James P. Allison, 70-year-old immunologist and native Texan, works at the prestigious Anderson Cancer Center in Houston. Tasuku Honjo is a 76-year-old immunologist and native of Kyoto, Japan who currently leads a variety of important medical research efforts at Kyoto University. Their research efforts span several decades, in two extremely different national contexts, but their recent international collaborations have reignited the profession over the last ten years.
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
We can conclude that radiation therapy is
Your Answer: Option(s)
Correct Answer: Option(s) D
Rationale
D) An older form of cancer treatment.
The extract discusses the innovative and groundbreaking work of James P. Allison and Tasuku Honjo in the field of immunotherapy, a relatively new and developing area in cancer treatment. This suggests that other forms of treatment, such as radiation therapy, have been in use for a longer time.
A) More successful than immunotherapy.
The extract does not provide any information comparing the success rates of radiation therapy and immunotherapy. It only highlights the significance and the groundbreaking nature of the research done in the field of immunotherapy.
B) More nonthreatening than immunotherapy.
The extract does not make any statement or suggest anything about the relative threat level of radiation therapy compared to immunotherapy. It only discusses the innovative research and potential of immunotherapy in treating cancer.
C) A new form of cancer treatment.
The information provided in the extract suggests the opposite. It discusses how immunotherapy is a relatively new and innovative field in cancer treatment, implying that radiation therapy is an older form of treatment.
D) An older form of cancer treatment.
This information can be inferred from the extract. The groundbreaking work done by Allison and Honjo in the field of immunotherapy is described as innovative and cutting-edge, suggesting that other forms of treatment, like radiation therapy, have been in use for a longer time.
Conclusion
The extract discusses the groundbreaking work of James P. Allison and Tasuku Honjo in the field of immunotherapy, a new and innovative area in cancer treatment. This implies that other forms of cancer treatment, such as radiation therapy, have been in existence for a longer period, making them older forms of treatment. There is no information in the extract that discusses the success rates or threat levels of radiation therapy compared to immunotherapy, or that suggests radiation therapy is a new form of treatment.
Select an answer to continue →
Question 4
1. In October 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology of Medicine for their groundbreaking efforts in inhibiting the impact of cancer in patients through immunotherapy. James P. Allison, 70-year-old immunologist and native Texan, works at the prestigious Anderson Cancer Center in Houston. Tasuku Honjo is a 76-year-old immunologist and native of Kyoto, Japan who currently leads a variety of important medical research efforts at Kyoto University. Their research efforts span several decades, in two extremely different national contexts, but their recent international collaborations have reignited the profession over the last ten years.
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
The best title for this article is
Your Answer: Option(s)
Correct Answer: Option(s) D
Rationale
Nobel Prize Winners Fight Cancer.
The article discusses the achievements of James P. Allison and Tasuku Honjo, who won the Nobel Prize for their revolutionary work in cancer immunotherapy. The title "Nobel Prize Winners Fight Cancer" is the most fitting as it directly reflects the main theme of the article.
A) Allison and Honjo Fight T-Cells.
This choice is incorrect because Allison and Honjo do not fight against T-Cells. Instead, their research focuses on using T-cell immunotherapy to fight cancer. Their work involves manipulating T-Cells to enhance the body's immune response against cancer cells. Therefore, this title could misrepresent their research.
B) CTLA-4 and PD-1: Two Deadly Types of Cancer.
This choice is incorrect because neither CTLA-4 nor PD-1 are types of cancer. They are proteins that play a role in regulating the immune system's response to cancer cells. Furthermore, the article does not specifically mention CTLA-4 or PD-1, making this title irrelevant to the content of the article.
C) Pharmacology and Cancer Treatments.
This choice is incorrect because it is too broad. While the research of Allison and Honjo does involve pharmacological treatments for cancer, the article focuses more specifically on their achievements in immunotherapy and their receipt of the Nobel Prize, not on the field of pharmacology as a whole.
D) Nobel Prize Winners Fight Cancer.
The correct title reflects the content of the article accurately. It highlights the major accomplishments of Allison and Honjo in the field of cancer research and their recognition as Nobel Prize winners.
Conclusion
The best title for this article is "Nobel Prize Winners Fight Cancer." This title concisely summarizes the main theme of the article, which is the groundbreaking work of James P. Allison and Tasuku Honjo in cancer immunotherapy, for which they were awarded the Nobel Prize. The other choices are either inaccurate or too broad to effectively represent the content of the article.
Select an answer to continue →
Question 5
1. In October 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology of Medicine for their groundbreaking efforts in inhibiting the impact of cancer in patients through immunotherapy. James P. Allison, 70-year-old immunologist and native Texan, works at the prestigious Anderson Cancer Center in Houston. Tasuku Honjo is a 76-year-old immunologist and native of Kyoto, Japan who currently leads a variety of important medical research efforts at Kyoto University. Their research efforts span several decades, in two extremely different national contexts, but their recent international collaborations have reignited the profession over the last ten years.
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
2. Together, their cutting-edge research has helped make cancer immunology one of the most innovative branches in the field of medicine. Their current project, which focuses on mitigating negative immune regulation, has helped uncover new strategies for “inhibiting the brakes of our immune systems” through T-cell immunotherapy. Though cancer rates continue to decline throughout developed countries, it still remains the second leading cause of global mortality rates, contributing to millions of deaths each year. Thanks to their findings, many research initiatives, which had previously given up on the prospects of immunotherapy practices, are reinvesting hundreds of millions of dollars into an entirely new class of drugs that might help
Since immunotherapy has shown some signs of success, it is reasonable to expect Allison and Honjo will
Your Answer: Option(s)
Correct Answer: Option(s) A
Rationale
Allison and Honjo will likely continue testing immunotherapy as a treatment for cancer.
Given their groundbreaking work in the field of immunotherapy, and the renewed interest and investment in this area, it is reasonable to anticipate that Allison and Honjo will continue their research. Their work has led to significant advancements in cancer treatment, and there is no indication that they intend to divert from this path.
A) Continue testing it as a treatment for cancer.
This choice aligns with the information provided, as the text emphasizes the importance and success of their work in immunotherapy. Given the promising results and ongoing challenges in cancer treatment, it would be logical for them to continue their research in this area.
B) Retire soon from the medical community.
The text does not provide any information to suggest that Allison and Honjo plan to retire soon. On the contrary, their work continues to have a significant impact, suggesting that they remain active in their field.
C) Write a book about their Nobel Peace Prize.
The text does not mention any plans for Allison and Honjo to write a book about their Nobel Prize. The Nobel Prize they were awarded is in Physiology or Medicine, not the Peace prize, and the focus of the text is on their research and its impact on cancer treatment, not on their accolades.
D) Focus on other treatments for cancer.
While it's possible that Allison and Honjo could focus on other treatments for cancer, there is no indication in the text that they plan to shift their focus away from immunotherapy. Their current work in immunotherapy is presented as groundbreaking and influential, implying they will continue in this area.
Conclusion
Based on the provided text, it is most reasonable to expect that Allison and Honjo will continue their research in immunotherapy for cancer treatment. Their work in this area has been recognized as groundbreaking, leading to a Nobel Prize and reigniting interest and investment in immunotherapy. The other options, while possible, are not supported by the information in the text.
Select an answer to continue →
Free Preview Ended
You've seen the first 5 questions.
Subscribe to unlock the remaining 15 questions + full features.
0%
score
0/0 correct
0
streak
Answered
0/20
Correct
0
Wrong
0
20 left
You are leaving this quiz
What would you like to do with your progress?
You're in the middle of a quiz
What would you like to do before switching?